Provention Bio Inc.s (PRVB) Teplizumab, proposed for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals, which was narrowly backed by an FDA panel in May, now awaits the final decision on July 2.The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 that the benefits of Teplizumab outweigh the risks.Despite the fact that the FDA is not required to obey the panel's advice, it is generally believed that it will.If approved, Teplizumab would be the first potential disease-modifying T1D therapy that will drive a paradigm shift in how individuals at risk of developing the disease are treated, according to the company.Teplizumab could achieve peak global sales of $691 million in 2027, according to a GlobalData consensus.PRVB closed Wednesday’s (Jun.23, 2021) trading at $8.38, up 0.12%.